These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 28258691)

  • 1. Viewing Siglecs through the lens of tumor immunology.
    Fraschilla I; Pillai S
    Immunol Rev; 2017 Mar; 276(1):178-191. PubMed ID: 28258691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Engagement of myelomonocytic Siglecs by tumor-associated ligands modulates the innate immune response to cancer.
    Läubli H; Pearce OM; Schwarz F; Siddiqui SS; Deng L; Stanczak MA; Deng L; Verhagen A; Secrest P; Lusk C; Schwartz AG; Varki NM; Bui JD; Varki A
    Proc Natl Acad Sci U S A; 2014 Sep; 111(39):14211-6. PubMed ID: 25225409
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance.
    Jandus C; Boligan KF; Chijioke O; Liu H; Dahlhaus M; Démoulins T; Schneider C; Wehrli M; Hunger RE; Baerlocher GM; Simon HU; Romero P; Münz C; von Gunten S
    J Clin Invest; 2014 Apr; 124(4):1810-20. PubMed ID: 24569453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Siglec-7 expression is reduced on a natural killer (NK) cell subset of obese humans.
    Rosenstock P; Horstkorte R; Gnanapragassam VS; Harth J; Kielstein H
    Immunol Res; 2017 Oct; 65(5):1017-1024. PubMed ID: 28786023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The membrane-proximal immunoreceptor tyrosine-based inhibitory motif is critical for the inhibitory signaling mediated by Siglecs-7 and -9, CD33-related Siglecs expressed on human monocytes and NK cells.
    Avril T; Floyd H; Lopez F; Vivier E; Crocker PR
    J Immunol; 2004 Dec; 173(11):6841-9. PubMed ID: 15557178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation?
    Cao H; Crocker PR
    Immunology; 2011 Jan; 132(1):18-26. PubMed ID: 21070233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sugar Free: Novel Immunotherapeutic Approaches Targeting Siglecs and Sialic Acids to Enhance Natural Killer Cell Cytotoxicity Against Cancer.
    Daly J; Carlsten M; O'Dwyer M
    Front Immunol; 2019; 10():1047. PubMed ID: 31143186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Siglec-6 as a New Potential Immune Checkpoint for Bladder Cancer Patients.
    Benmerzoug S; Chevalier MF; Verardo M; Nguyen S; Cesson V; Schneider AK; Dartiguenave F; Rodrigues-Dias SC; Lucca I; Jichlinski P; Roth B; Nardelli-Haefliger D; Derré L
    Eur Urol Focus; 2022 May; 8(3):748-751. PubMed ID: 34147404
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Basic and clinical immunology of Siglecs.
    von Gunten S; Bochner BS
    Ann N Y Acad Sci; 2008 Nov; 1143():61-82. PubMed ID: 19076345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cloning, characterization, and phylogenetic analysis of siglec-9, a new member of the CD33-related group of siglecs. Evidence for co-evolution with sialic acid synthesis pathways.
    Angata T; Varki A
    J Biol Chem; 2000 Jul; 275(29):22127-35. PubMed ID: 10801860
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probing sialic acid binding Ig-like lectins (siglecs) with sulfated oligosaccharides.
    Rapoport EM; Pazynina GV; Sablina MA; Crocker PR; Bovin NV
    Biochemistry (Mosc); 2006 May; 71(5):496-504. PubMed ID: 16732727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High-affinity ligands of Siglec receptors and their therapeutic potentials.
    Magesh S; Ando H; Tsubata T; Ishida H; Kiso M
    Curr Med Chem; 2011; 18(23):3537-50. PubMed ID: 21756229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The sialoglycan-Siglec glyco-immune checkpoint - a target for improving innate and adaptive anti-cancer immunity.
    Bärenwaldt A; Läubli H
    Expert Opin Ther Targets; 2019 Oct; 23(10):839-853. PubMed ID: 31524529
    [No Abstract]   [Full Text] [Related]  

  • 14. Siglecs: sialic-acid-binding immunoglobulin-like lectins in cell-cell interactions and signalling.
    Crocker PR
    Curr Opin Struct Biol; 2002 Oct; 12(5):609-15. PubMed ID: 12464312
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Negative regulation of T cell receptor signaling by Siglec-7 (p70/AIRM) and Siglec-9.
    Ikehara Y; Ikehara SK; Paulson JC
    J Biol Chem; 2004 Oct; 279(41):43117-25. PubMed ID: 15292262
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting glycosylated antigens on cancer cells using siglec-7/9-based CAR T-cells.
    Meril S; Harush O; Reboh Y; Matikhina T; Barliya T; Cohen CJ
    Mol Carcinog; 2020 Jul; 59(7):713-723. PubMed ID: 32391973
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting sialic acid-Siglec interactions to reverse immune suppression in cancer.
    Adams OJ; Stanczak MA; von Gunten S; Läubli H
    Glycobiology; 2018 Sep; 28(9):640-647. PubMed ID: 29309569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduced Siglec-7 expression on NK cells predicts NK cell dysfunction in primary hepatocellular carcinoma.
    Tao L; Wang S; Yang L; Jiang L; Li J; Wang X
    Clin Exp Immunol; 2020 Aug; 201(2):161-170. PubMed ID: 32319079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of CD33-related siglecs on human mononuclear phagocytes, monocyte-derived dendritic cells and plasmacytoid dendritic cells.
    Lock K; Zhang J; Lu J; Lee SH; Crocker PR
    Immunobiology; 2004; 209(1-2):199-207. PubMed ID: 15481154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Siglec-5 is an inhibitory immune checkpoint molecule for human T cells.
    Vuchkovska A; Glanville DG; Scurti GM; Nishimura MI; White P; Ulijasz AT; Iwashima M
    Immunology; 2022 Jun; 166(2):238-248. PubMed ID: 35290663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.